1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Patient-Reported Data In COVID-Impacted Trials: US FDA Cautions Against Missing Data, Potential Bias

 
• By Sue Sutter

Considerations for switching from in-person to remote collection of patient- and observer-reported outcomes addressed in latest update to Q&A guidance, which also discusses Part 11 compliance requirements in the context of the pandemic and electronic collection of informed consent through MyStudies app.

Pc monitor view over girl shoulder, old doctor wear uniform headset give consultation to client via internet about epidemic outbreak of corona virus ncov, distant communication and protection concept
US FDA outlines issues to consider in switching to remote collection of patient-reported outcomes. • Source: Shutterstock

Clinical trial sponsors should consider the potential for missing data and bias when deciding whether to switch from in-person to remote collection of observer-reported and patient-reported outcome assessments during the COVID-19 pandemic, the US Food and Drug Administration says.

In the latest update to its question-and-answer guidance on managing the novel coronavirus’ impact on clinical trials, the agency...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Cancer Drug Trials Must Be Ready To Pivot As Standards Of Care Shift

 
• By Sue Sutter

Upfront planning is critical to navigating a change in the standard of care while a randomized registrational trial is underway. Sponsors must also be mindful to what patients and clinicians will consider an acceptable comparator arm, a new white paper states.

Biohaven’s Troriluzole And The Era Of Real-Time Complete Response Letters

 
• By Michael McCaughan

US FDA’s rejection of Biohaven’s troriluzole is a huge disappointment for patients with SCA and the company. But it is also a notable example of how communication strategies are changing now that FDA is making its ‘complete response’ letters public.

Brazil To Fix Regulatory Reliance Shortfalls & Speed Up Approvals

 
• By Francesca Bruce

Regulatory reliance processes for drug registration and clinical trial application approvals in Brazil have not met their “full potential,” says Brazil’s medicines regulator.

UK Targets Contamination Tests & Pharmacokinetic Studies In Animal Testing Phase Out

 
• By Eliza Slawther

Pharmaceutical companies will be expected to phase out certain animal tests in the drug development process under a UK roadmap aimed at pivoting towards using alternative models, such as organ-on-a-chip systems and artificial intelligence.

More from R&D

Novel Oncology Endpoints Take Time, Require Broad Outreach, US FDA Says

 
• By cole werble

The US FDA’s oncology team is emphasizing a methodical approach to developing novel endpoints like MRD or ctDNA and that community buy-in is important, not just regulatory standards.

Where RWE Studies Stand In India And Bharat Serums’ Plans For The World’s Largest One

 
• By Vibha Ravi

Real-world evidence (RWE) studies in India face challenges like lack of data reliability and uniformity and absence of clear guidelines but firms like Bharat Serums have scored a regulatory win. Pink Sheet examines the RWE landscape and the BSV case study for lessons in beating the odds

UniQure Is Latest Gene Therapy Sponsor Surprised By US FDA Reversal

 
• By Bridget Silverman

UniQure’s Huntington's disease filing plans are in disarray after the FDA reversed course on the company's regulatory strategy employing real-world evidence and accelerated approval.